US 12,325,726 B2
Organic compounds
Kimberly Vanover, New York, NY (US); Peng Li, New Milford, NJ (US); Robert Davis, San Diego, CA (US); and Yupu Qiao, New York, NY (US)
Assigned to INTRA-CELLULAR THERAPIES, INC., Bedminster, NJ (US)
Appl. No. 17/415,667
Filed by INTRA-CELLULAR THERAPIES, INC., New York, NY (US)
PCT Filed Dec. 17, 2019, PCT No. PCT/US2019/066923
§ 371(c)(1), (2) Date Jun. 17, 2021,
PCT Pub. No. WO2020/131918, PCT Pub. Date Jun. 25, 2020.
Claims priority of provisional application 62/780,703, filed on Dec. 17, 2018.
Prior Publication US 2022/0073558 A1, Mar. 10, 2022
Int. Cl. C07B 59/00 (2006.01); A61K 31/58 (2006.01); A61P 23/00 (2006.01); A61P 25/00 (2006.01); A61P 25/20 (2006.01); C07J 43/00 (2006.01)
CPC C07J 43/003 (2013.01) [C07B 2200/05 (2013.01)] 28 Claims
 
1. A compound of a Formula I:

OG Complex Work Unit Chemistry
wherein:
X is selected from H, —(C═O)—Ra, —CH2—(C═O)—O—Ra, and —CH2—(C═O)—N(Ra)(Rb);
R1 is selected from CH3, CDH2, CD2H and CD3;
each of R2 to R9 is independently selected from H and D;
Ra and Rb are independently selected from H, C1-20alkyl, and C1-4alkyl-aryl;
in free or pharmaceutically acceptable salt form,
provided that if R1 is CH3 and R2 to R9 are all H, then X is selected from —(C═O)—Ra, —CH2—(C═O)—O—Ra, and —CH2—(C═O)—N(Ra)(Rb).